Clinical

The program will initially allow 6 sponsors of clinical trials to participate and will provide sponsors with the opportunity for frequent advice and regular communication regarding clinical trial design and other development issues.

A co-expression network analysis pinpoints different gene expressions that can potentially predict rheumatoid arthritis (RA) outcomes during pregnancy.

There are many immunotherapy-caused skin toxicities, but most can be easily managed.

Updated findings from a phase 1/2 trial of stem-cell derived islet cell therapy for type 1 diabetes (T1D) showed improved glycemic control and a reduction in insulin dependence.

The rare disease Fanconi anemia is an inherited bone marrow disorder linked to birth defects that leads to failure of bone marrow, the spongy material inside the bones where stem cells develop.

Age-related macular degeneration (AMD) and impaired vision were found to be associated with choriocapillaris flow signal deficits in patients 60 years and older.

Clostridioides difficile (C difficile) screening in all ICU admissions identified asymptomatic carriers and their risk for developing and/or transmitting infection.

FDA is investigating fraudulent schemes trafficking counterfeit semaglutide (Ozempic); Moderna plans to begin a late-stage trial of its combined COVID-19 and flu vaccine later this year; CMS will begin restricting predictive software used by insurance companies next year.

A recent study suggests that a patient’s immune microenvironment plays a key role in the depth and duration of response to multiple myeloma treatment.

Researchers found that patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (RT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy.

The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.

These findings support the importance of children with atopic dermatitis (AD) receiving patch testing to consider allergic contact dermatitis as a comorbidity.

In a multidisciplinary follow-up study, researchers analyzed bone health decline and the effects of nusinersen in patients with spinal muscular atrophy (SMA) types 2 and 3.

The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis.

Specialists evaluate their clinical strategies for managing second-line driver-negative and initial PD-L1 negative patients.

The researchers noted that their findings suggest clinicians and policy makers should encourage hepatitis C virus (HCV) treatment in those with unhealthy alcohol consumption or alcohol use disorder (AUD) rather than create barriers to it.

Medical experts discuss considerations for ESRD during CKD treatment as well as updated guidelines for treatment of chronic kidney disease.

Jennifer Green, MD, provides considerations for the use of SGLT2 inhibitors in treatment of CKD.

Following discussions with FDA, Takeda will voluntarily withdraw mobocertinib in the United States for adult patients with EGFR exon 20 insertion mutation–positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) based on the outcomes of the phase 3 EXCLAIM-2 trial.

Major companies committed to joining Medicare drug price negotiations; Boehringer Ingelheim introduced a low-cost version of its adalimumab biosimilar; schools begin to stock naloxone amid rising opioid deaths among young people.

The chosen studies featured various methods to assess medication use initiation, implementation, and/or persistence in patients with chronic obstructive pulmonary disease (COPD).

Severe cases of COVID-19 and COVID-19–related deaths were associated with sickle cell disease.

Nedosiran (Rivfloza) was approved for children and adults with primary hyperoxaluria type 1 (PH1), according to drugmaker Novo Nordisk.

Atrioventricular interval modulation (AVIM) therapy for hypertension may help address this common comorbidity among patients with pacemakers.